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Abstract
Elongation factor 1A-1 (eEF1A-1) was previously identified as a mediator of fatty
acid-induced cell death (lipotoxicity) downstream of endoplasmic reticulum (ER) stress.
Furthermore, inhibition of the peptide elongation activity of eEF1A-1 with the cyclic
depsipeptide didemnin B (DB) diminishes ER stress and lipotoxicity in cultured hepatocytes.
Since ER stress is involved in nonalcoholic fatty liver disease (NAFLD), it was hypothesized
that administration of DB to obese mice with NAFLD would reduce hepatic lipotoxicity.
Treatment with DB for one week improved several parameters associated with hepatic
lipotoxicity and modestly decreased food intake without evidence of illness. Liver
triglycerides and protein markers of ER stress, plasma measurements of liver enzymes,
plasma cholesterol, and glucose homeostasis were all improved. Of these observations, only
improved plasma liver enzymes and glucose homeostasis were completely attributed to
reduced food intake. It was concluded that acute intervention with DB improved hepatic
lipotoxicity in obese mice with NAFLD.
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Chapter 1

1

Introduction

1.1

Obesity and Metabolic Syndrome
Over the past several decades, diet-induced obesity has steadily become a major

health concern in North America (Unger and Scherer, 2010). Obesity is defined as the
accumulation of excess body fat to such an extent that it may lead to adverse health
effects (Navaneelan and Janz, 2014). Body mass index (BMI) is a well established
diagnostic tool used to measure obesity. BMI is calculated by dividing a person’s weight
in kilograms by their height in metres squared (Despres, 2015). A person with a BMI
greater than 25 kg/m2 is classified as overweight, whereas a person with a BMI greater
than 30 kg/m2 is classified as obese (Kramer, 2015). Although the relationship between
an increase in BMI and adverse health outcomes is well established, the diagnostic test is
not without its limitations. The assessment of adipose by BMI does not take into
consideration total body composition, including visceral fat and abdominal obesity.
Furthermore, although increased BMI is an indicator of health risks associated with
dysregulated metabolism, not all individuals with increased weight experience metabolic
complications and are therefore considered metabolically healthy obese (Gustafson et al.,
2015). The consequences of overnutrition and inactivity are numerous. Being overweight
or obese is associated with increased risk of developing many other conditions including
dyslipidemia, type II diabetes, hypertension, heart disease, stroke, sleep apnea,
degenerative joint disease, and cancer, among others (Kramer, 2015). The predominant
cause of obesity is an imbalance in caloric consumption and energy expenditure.
According to Statistics Canada, one in four adult Canadians, approximately 6.3 million
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people, were classified as obese in 2011. Since 2003, there has been a 17.5% increase in
the number of Canadians classified as obese (Navaneelan and Janz, 2014).
A subset of risk factors for cardiovascular disease and diabetes, that are
commonly associated with obesity, have been grouped and described as the metabolic
syndrome (Alberti et al., 2009). Metabolic syndrome is defined by abdominal obesity
plus two of the following characteristics: elevated fasting blood glucose (≥5.6 mmol/l),
elevated plasma triglycerides (≥1.7 mmol/l), elevated blood pressure (≥130/85 mm Hg),
and decreased high-density lipoprotein (HDL) cholesterol (<1.03 mmol/l) (Simmons et
al., 2010; Wagh and Stone, 2004). Obesity and metabolic syndrome have reached
epidemic proportions and continue to increase at an alarming rate. The prevalence of
these health concerns no longer affects only the Western world and is now a serious
public health issue for low and middle-income countries (Unger and Scherer, 2010).
Obesity and metabolic syndrome are associated with lipid accumulation in nonadipose tissues. Most cells and tissues have a limited ability to store excess lipid. The
primary function of adipose and adipocytes is to store excess calories as lipid during a fed
state, and distribute lipid to non-adipose tissues for energy generation during a fasted
state (Unger and Scherer, 2010). During times of caloric excess and inactivity,
subcutaneous adipose tissue will initially accommodate excess lipid through the
expansion and hypertrophy of adipocytes (Gustafson et al., 2015). However, adipose
tissue also has a limited storage capacity. If this capacity is exceeded, adipocyte
dysfunction and uncontrolled lipolysis ensue, resulting in elevated circulating free fatty
acids. In the liver, chronic exposure to increased circulating free fatty acids, which can
occur during obesity, leads to hepatic insulin resistance. Under physiological conditions
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during the fed state, insulin suppresses hepatocyte export of excess lipid as very lowdensity lipoprotein (VLDL) (Sparks et al., 2012). Hepatic insulin resistance impairs the
ability of the liver to downregulate the production of VLDL, leading to the
overproduction and secretion of VLDL, and resulting in hypertriglyceridemia (Adeli et
al., 2001). This increase in serum triglycerides and flux of free fatty acids from adipose
and liver leads to the accumulation of lipid in non-adipose tissues such as the pancreas,
heart and vasculature, skeletal muscle, and kidney (Brookheart et al., 2009) (Figure 1.1).
Deposition of lipid in these tissues can result in tissue specific insulin resistance,
inflammation, and cell dysfunction and death (Unger and Scherer, 2010). This
accumulation of lipid in non-adipose tissue resulting in the disruption of cellular
homeostasis and contributing to cell death is termed lipotoxicity (Aon et al., 2014;
Wende et al., 2012). Thus, chronic exposure of non-adipose tissue to elevated
concentrations of lipids and the accumulation of excess lipid in these organs causes
cellular dysfunction, and can lead to the development of disease (Unger and Scherer,
2010).
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Figure 1.1 Obesity results in ectopic lipid deposition in a variety of organs and
tissues.
A diet high in calories and fat along with an inactive lifestyle leads to elevated circulating
blood glucose, free fatty acids (FA) and triglycerides (TG). Chronic exposure to caloric
overload overwhelms the ability of adipose tissue to expand, resulting in adipose failure.
This leads to a flux of free fatty acids from adipose tissue into the circulation, and
eventually lipid accumulation in non-adipose tissues such as the pancreas, skeletal
muscle, heart and vasculature, and liver (represented by yellow circles). Chronic
exposure to excess free fatty acids impairs the ability of the liver to downregulate the
production of VLDL, leading to VLDL overproduction and hypertriglyceridemia.
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1.2

Nonalcoholic Fatty Liver Disease
Increased

dietary intake of high calorie and high fat foods, coupled with a

reduction in physical activity leads to an increase in the circulating levels of free fatty
acids, and consequently an increase in the storage of triglycerides in non-adipose tissues
such as the liver (Leamy et al., 2013). Nonalcoholic fatty liver disease (NAFLD)
represents a spectrum of lipid accumulation in the liver from benign steatosis (fatty
infiltration of the liver) to nonalcoholic steatohepatitis (NASH) (steatosis accompanied
by inflammation and hepatocyte necrosis), in the absence of excessive alcohol
consumption (Bayard et al., 2006). NAFLD is strongly associated with obesity and
insulin resistance. It is considered the hepatic manifestation of metabolic syndrome and is
now the most common chronic liver disease, affecting 75-80% of obese patients, or
approximately 20% of the general population in the Western world (Tuyama and Chang,
2012). Not all patients diagnosed with hepatic steatosis progress to NASH
(Neuschwander-Tetri, 2010). However, as a result of the prevalence of obesity, NASH is
now the third most common indication for liver transplant in the United Sates, and is
projected to be the leading cause of liver transplant within the next two decades (Wang et
al., 2014b). NASH is associated with significant hepatocyte lipotoxicity, advanced
fibrosis and cirrhosis, and can lead to the development of hepatocellular carcinoma and
end stage liver disease (Tuyama and Chang, 2012).
The diagnosis and staging of NAFLD is a complex process that often begins when
laboratory test results show elevated liver enzymes (Tuyama and Chang, 2012). To
confirm a diagnosis of NAFLD, alcoholic fatty liver disease and viral hepatitis must first
be excluded. Daily alcohol consumption must be below 20 g per day for women and 30 g
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per day for men to exclude alcoholic fatty liver disease (Bayard et al., 2006). The main
histological characteristic of NASH is the displacement of the nucleus to the edge of the
cell. Hepatocyte ballooning, lobular neutrophilic inflammation and Mallory bodies can
also be present (Sanyal, 2002). Elevated plasma alanine transaminase (ALT) and
aspartate transaminase (AST) are non-invasive diagnostic markers of liver function
(Sanyal, 2002). ALT and AST are enzymes located in hepatocytes that are released into
the circulation upon liver injury. The ratio of AST/ALT is usually less than 1 but
increases as the severity of liver damage increases (Bayard et al., 2006). However, the
reliability of liver enzymes alone as a diagnostic tool for staging NAFLD has been
debated due to the poor sensitivity and specificity of the test. Many patients with NASH
have AST and ALT levels that fluctuate within the normal limit (Adams and Feldstein,
2011). The presence of liver steatosis can be diagnosed by various imaging techniques
such as ultrasound, computerized tomography (CT) scan, and magnetic resonance
imaging (MRI). Of these, the least expensive and most commonly used method is
ultrasound, whereas MRI is the most accurate yet most expensive method (Chalasani et
al., 2012). Despite the efficacy of these routine imaging techniques in detecting steatosis,
they are unable to distinguish fatty liver from the early stages of NASH (Adams and
Feldstein, 2011). Liver biopsy remains the only accurate method to diagnose NASH,
however, biopsies sample only a very small portion of the liver and carry a risk of
morbidity and mortality and therefore should be performed with caution in patients who
would benefit the most from diagnostic guidance (Chalasani et al., 2012).
The progression of NAFLD, from benign steatosis to NASH, is complex and its
pathogenesis is not fully understood. However, lipid accumulation in the liver, the
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primary gross morphological characteristic of NAFLD, can be attributed to insulin
resistance (Utzschneider and Kahn, 2006). Patients with NAFLD generally exhibit a
reduction in whole-body insulin sensitivity that is driven by insulin resistance in
peripheral tissues including skeletal muscle, adipose tissue, and liver (Trauner et al.,
2010). Insulin resistance is associated with impaired suppression of adipose lipolysis, and
thus increased supply of free fatty acids to the liver. Furthermore, the compensatory
hyperinsulinemia that occurs during insulin resistance can lead to an increase in de novo
lipogenesis through the activation of sterol receptor binding protein 1-c (SREBP-1c), a
transcription factor that regulates expression of lipogenic genes (Utzschneider and Kahn,
2006). Hyperinsulinemia can also suppress forkhead box protein FOXA2, which leads to
a decrease in fatty acid oxidation and further accumulation of lipid in the liver. Insulin
resistance also leads to a reduction in glucose uptake by adipose tissue and skeletal
muscle, leading to hyperglycemia (Ahmed et al., 2015). This resulting hyperglycemia can
activate carbohydrate response element binding protein (ChREBP) in hepatocytes, a
transcription factor which stimulates lipogenesis even further by regulating the
conversion of excess glucose to fatty acids (Utzschneider and Kahn, 2006). Thus, insulin
resistance is thought to be very important for the initiation and progression of NAFLD.
NAFLD has become a major cause of liver-related morbidity in North America.
As the prevalence of risk factors such as metabolic syndrome, type 2 diabetes, and
obesity have increased, the prevalence of NAFLD has also increased (Sanyal, 2002). It is
not known why some patients with NAFLD progress to NASH and end stage liver
disease while others remain asymptomatic, with only benign hepatic steatosis for their
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entire life. This suggests that other factors, including genetic and environmental
determinants, play a role in the progression of the spectrum of disease.

1.3

Lipotoxicity in Cultured Hepatocytes
NAFLD is first characterized by an accumulation of neutral lipid, mostly in the

form of triglycerides, in hepatocytes. As noted in the previous section, progression of this
disease is associated with insulin resistance and elevated serum free fatty acids (Nehra et
al., 2001; Tessari et al., 2009). Fatty acids that contribute to hepatic steatosis originate
from three main sources. The majority (60%) comes from the release of free fatty acids
stored in adipose tissue. Fatty acids made in the liver through de novo lipogenesis are the
next most significant contributing factor, responsible for up to 30% of stored hepatic lipid
content. Finally, dietary fatty acids contribute approximately 10% of hepatic lipid content
(Firneisz, 2014; Ibrahim et al., 2011; Musso et al., 2009). Free fatty acids, that originate
from dietary fat or lipolysis of triglycerides stored in adipose, are carried in the
circulation bound to albumin (Bradbury, 2006; van der Vusse, 2009). When circulating
free fatty acid concentrations are high they are taken up by the hepatocyte through flipflop or facilitated transport. Fatty acid transport proteins (FATP), in particular FATP5,
have been implicated in the facilitation of fatty acid uptake at the liver (Musso et al.,
2009). Once transported into the hepatocyte, fatty acids can be converted to triglycerides
and either stored as lipid droplets in the cytosol or exported in VLDL (Bradbury, 2006;
Hegele, 2009). Fatty acids can also undergo β-oxidation in the mitochondria (Musso et
al., 2009; Tessari et al., 2009). When hepatocytes are overwhelmed by excess lipid, in
particular saturated fatty acids, lipotoxic response pathways are activated leading to
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oxidative and endoplasmic reticulum (ER) stress, ultimately resulting in cell dysfunction
and death (Brookheart et al., 2009; Wei et al., 2006).

1.3.1 Saturated and Unsaturated Fatty Acids
In vitro models of hepatocyte steatosis have been useful in the study of the
consequences of lipid accumulation and lipotoxicity in the liver. For these models,
hepatocyte cell lines or primary hepatocytes are treated with pathophysiological
concentrations of saturated and unsaturated fatty acids conjugated to bovine serum
albumin (BSA) (Leamy et al., 2013). Fatty acid treatments can be varied to reflect a
typical Western diet and the conditions the liver is exposed to during obesity and
metabolic syndrome (Soriguer et al., 2009).
Studies in cultured liver cells and in rodent models of NAFLD have demonstrated
that saturated fatty acids, such as palmitate, the most common saturated fatty acid in
Western diets, are more harmful to hepatocytes than unsaturated fatty acids, such as
oleate (Leamy et al., 2013; Listenberger et al., 2003; Wei et al., 2006). Saturated fatty
acids, in contrast to unsaturated fatty acids, preferentially undergo β-oxidation at the
mitochondria and produce substrates for the synthesis of ceramide; a lipid second
messenger involved in apoptosis. β-oxidation of saturated fatty acids can also produce
reactive oxygen species (ROS) that lead to cellular dysfunction by triggering the unfolded
protein response (UPR) and ER stress response (Faust and Kovacs, 2014; Wei et al.,
2006). Furthermore, unsaturated fatty acids are readily incorporated into triglycerides
whereas saturated fatty acids are inefficiently esterified and stored as triglycerides
(Listenberger et al., 2003). Co-incubation of hepatocytes with both saturated and
unsaturated fatty acids prevents palmitate toxicity by diverting saturated fatty acids to
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triglyceride formation (Li et al., 2009; Listenberger et al., 2003). Inhibition of stearoylCoA desaturase-1 (SCD1), the enzyme responsible for converting saturated fatty acids to
unsaturated fatty acids, sensitizes hepatocytes to saturated fatty acid induced apoptosis
(Li et al., 2009). Furthermore, scd1

knockout mice fed a methionine and choline

deficient diet, which induces NAFLD, accumulate less triglyceride in the liver compared
to wild-type mice but have increased serum free fatty acid levels, liver damage, and
fibrosis. However, scd1 knockout mice fed a methionine and choline deficient diet
supplemented with oleate have less severe apoptosis and liver injury (Li et al., 2009).
Taken together, these studies support the concept that it is saturated, and not unsaturated,
fatty acids that are primarily responsible for hepatocyte lipotoxicity.

1.3.2 Endoplasmic Reticulum Stress
The ER is an organelle essential for many different cellular functions including
protein synthesis, folding and modification, calcium homeostasis, lipid synthesis, and
carbohydrate metabolism (Ji and Kaplowitz, 2006). Due to the high anabolic burden at
the ER during NAFLD, not all synthesized proteins are able to be properly folded and
processed. This disruption of ER homeostasis by lipid excess, which can also occur
through other stressors such as oxidative stress and disruption of calcium homeostasis,
results in the accumulation of unfolded or misfolded proteins in the ER lumen, and leads
to ER stress (Zhou and Liu, 2014). To restore ER homeostasis, eukaryotic cells have
developed the unfolded protein response (UPR); a physiological process to ensure proper
protein folding and efficiently remove misfolded proteins from the ER. Activation of the
UPR inhibits protein synthesis, increases protein folding, and eliminates unfolded
proteins through degradation in an effort to reduce the burden at the ER (Zhou and Liu,
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2014). The UPR is initially protective; however, if the UPR is unable to restore
homeostasis, the ER stress response is activated in order to initiate cell death pathways
(De Minicis et al., 2012; van der Kallen et al., 2009).
The UPR activates intracellular signaling pathways mediated by three ER
localized protein sensors: inositol-requiring enzyme 1α (IRE1α), activating transcription
factor 6 (ATF6), and double stranded RNA-dependent like ER kinase (PERK) (Ji and
Kaplowitz, 2006). These protein sensors span the ER membrane and under physiological
conditions are bound to the protein folding chaperone glucose-related protein 78
(GRP78), also known as binding immunoglobulin protein (BiP), in an inactive state
(Zhou and Liu, 2014). In response to the accumulation of unfolded or misfolded proteins,
GRP78 dissociates from the protein sensors, resulting in their activation, and binds to its
unfolded or misfolded protein targets. When GRP78 dissociates from IRE1α, IRE1α is
autophosphorylated and induces the production of the spliced form of X box binding
protein 1 (XBP1) which regulates the expression of genes encoding protein folding
chaperones and factors to help restore ER homeostasis (Ozcan et al., 2004). IRE1α also
induces the activation of stress kinases such as c-Jun-N-terminal kinase (JNK) that
promote apoptosis (Ibrahim and Gores, 2012). When GRP78 dissociates from ATF6,
ATF6 translocates to the Golgi apparatus, where it is cleaved into its active form. The
active form of ATF6 translocates to the nucleus and acts as a transcription factor to
promote the expression of UPR target genes such as GRP78, XBP1 and C/EBPhomologous protein (CHOP) (Ji and Kaplowitz, 2006; Zhou and Liu, 2014). When
GRP78 dissociates from PERK, PERK phosphorylates eukaryotic translation initiation
factor 2α (eIF2α) resulting in the inhibition of protein synthesis. However, with sustained
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ER stress, PERK activity promotes the translation of ATF4, which in turn promotes the
transcription of genes involved in apoptosis, such as CHOP (Ji and Kaplowitz, 2006;
Jiang et al., 2014). The UPR and ER stress response are important cellular mechanisms
that have been implicated in the hepatocellular response to saturated fatty acid excess.
Both in vitro (cultured hepatocytes) and in vivo (dietary and genetic) models of NAFLD
are associated with increased expression of UPR and ER stress markers such as CHOP,
GRP78, phosphorylated JNK, phosphorylated PERK, and phosphorylated eIF2α (Cao et
al., 2012; Ibrahim and Gores, 2012; Ozcan et al., 2004; Wei et al., 2006).

1.3.3 Oxidative Stress and Mitochondrial Dysfunction
In addition to ER stress, elevated levels of ROS, leading to oxidative stress and
mitochondrial dysfunction, have been shown to play a role in hepatic cytotoxic cell
response and NASH progression (Leamy et al., 2013). The elevated levels of ROS
associated with saturated fatty acid overload in hepatocytes can be attributed to increased
mitochondrial β-oxidation, increased expression of cytochrome P450 2E1 (CYP2E1) and
CYP4A; the enzymes responsible for the oxidative metabolism of long chain fatty acids,
and upregulation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
(Koek et al., 2011; Li et al., 2008; Park et al., 2014). The majority of fatty acids are
metabolized through β-oxidation at the mitochondria. β-oxidation shortens fatty acids
into acetyl-CoA subunits which either enter into the tricarboxylic acid cycle and are
further oxidized to water and carbon dioxide or are condensed into ketone bodies and
serve as energy substrates for other tissues (Musso et al., 2009). When mitochondrial
oxidative capacity becomes impaired, fatty acids accumulate in the cytosol and alternate
oxidative pathways in peroxisomes and microsomes are activated, resulting in an increase
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in ROS (Musso et al., 2009). ROS, such as anion peroxide and hydrogen peroxide
(H2O2), are a normal byproduct of the mitochondrial respiratory chain and are produced
at complex I and complex III (Brenner et al., 2013; Koek et al., 2011). Under
physiological conditions, the cytotoxic effects of ROS are mitigated by antioxidant
systems and enzymatic scavengers including dismutases, peroxidases, and glutathione,
among others (Brenner et al., 2013; Brookheart et al., 2009). However, in
pathophysiological conditions, when ROS levels exceed the buffer capacity of these
systems, they trigger an inflammatory response that leads to oxidative damage,
mitochondrial dysfunction and the activation of cell death pathways (Brenner et al.,
2013). Excess ROS cause damage to proteins, DNA, lipids, compromise membrane
integrity, and trigger the upregulation of pro-inflammatory cytokines such as tumor
necrosis factor-α (TNFα) (Brookheart et al., 2009; Koek et al., 2011).
The underlying mechanism of mitochondrial dysfunction is very complex and the
molecular mechanisms responsible remain poorly understood. Mitochondrial dysfunction
is characterized by mitochondrial outer-membrane permeabilization, caspase activation
and release of cytochrome c into the cytosol (Li et al., 2008). Increased ROS production
is a consequence of this dysfunction but has also been shown to contribute to dysfunction
(Litvinova et al., 2015). Lipid peroxidation products and TNFα inhibit the electron
transport chain, and damage mitochondrial DNA resulting in impaired function and an
increase in the production of ROS. Mitochondrial dysfunction also results in the
inhibition of β-oxidation of lipids, leading to the accumulation of excess fatty acids in the
cytosol, where they can further contribute to hepatic steatosis by being incorporated into
neutral lipids (Koek et al., 2011). In liver tissue of patients with NASH, mitochondrial
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function and mitochondrial respiratory chain activity has been shown to be impaired
(Agrawal and Duseja, 2012; Litvinova et al., 2015; Perez-Carreras et al., 2003). Along
with these functional irregularities, mitochondrial structural changes, including
longitudinal or spherical swelling and the development of intramitochondrial crystals
consisting of phospholipids, have been observed in patients with steatohepatitis (Caldwell
et al., 2009; Sanyal et al., 2001). Taken together, there is significant evidence to support
that the complex relationship between oxidative stress and mitochondrial dysfunction
plays a key role in the pathogenesis and progression of NAFLD.

1.3.4 Modes of Cell Death in NAFLD: Necrosis and Apoptosis
There are several modes of cell death that are involved in hepatocellular
lipotoxicity and associated with the progression of NAFLD. Necrosis, apoptosis,
necroptosis, and autophagy have all been shown to occur in hepatocytes. Necrosis is an
unregulated consequence of cell stress characterized by mitochondrial impairment, a
decrease in adenosine triphosphate (ATP), and failure of ATP-dependent ion pumps. This
leads to cellular swelling, mitochondrial swelling, the formation of membrane blebs, and
ultimately cell rupture and the activation of inflammatory responses (Lemasters et al.,
2009; Luedde et al., 2014). Apoptosis, or programmed cell death, is a highly regulated
process mediated by aspartate specific proteases known as caspases. It is characterized by
cell shrinkage, nuclear condensation and fragmentation, and plasma membrane blebbing
leading to the production of apoptotic bodies (Luedde et al., 2014; Schattenberg et al.,
2006). Due to the engulfment of these apoptotic bodies by macrophages, apoptosis,
unlike necrosis, does not typically generate an inflammatory response within tissues.
Apoptosis can be initiated through an intrinsic or extrinsic pathway. In hepatocytes, the
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intrinsic pathway can be triggered by ER stress, JNK activation, and p53 activation. This
pathway initiates apoptosis through members of the B-cell lymphoma 2 (BCL2) family
which regulate mitochondrial outer membrane permeabilization, cytochrome c release,
and caspase activation (Luedde et al., 2014; Martinou and Youle, 2011). The extrinsic
pathway is triggered by cytokines such as members of the TNF ligand superfamily, and
the downstream activation of caspases (Schattenberg et al., 2006). Caspases cleave
proteins whose loss of function induces apoptosis. Apoptosis in the liver is mediated by
both extrinsic and intrinsic pathways as hepatocytes require mitochondrial amplification
via cytochrome c release mediated activation of caspase 3 for efficient cell death (Luedde
et al., 2014; Scaffidi et al., 1998). Apoptosis and the controlled elimination of cells is an
important regulator of liver homeostasis however, this mechanism of hepatocyte cell
death can become excessive during hepatic steatosis, contributing to the progression of
NAFLD and NASH. Necroptosis incorporates features of both necrosis and apoptosis and
is defined as necrotic cell death dependent on receptor interacting protein kinases (RIPK)
1 and 3 (Linkermann and Green, 2014). The cellular pathways involved in necroptosis
are not well understood and there is little evidence for its involvement in NAFLD,
however, it is difficult to differentiate between necrosis and necroptosis in vivo
(Guicciardi et al., 2013). Necroptosis is believed to act as a backup cell death pathway
when apoptosis is inhibited. Like necrosis, necroptosis results in cellular swelling, cell
leakage, and immune responses and is a caspase-independent form of cell death triggered
by TNFα and other death receptors and toll-like receptors (Kaczmarek et al., 2013;
Linkermann and Green, 2014; Luedde et al., 2014). A general model of lipotoxic cell
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death in hepatocytes including the pathways described in this section is shown in Figure
1.2.
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Figure 1.2 Pathways involved in hepatocyte lipotoxicity.
Excess saturated fatty acids, such as palmitate, can overwhelm the ability of a hepatocyte
to store them as triglycerides (lipid droplets), to catabolise them through β-oxidation in
the mitochondria, and to export them as triglycerides in lipoproteins. This can result in
the production of reactive oxygen species (ROS) which can lead to oxidative and ER
stress. Excess palmitate can also impair the structure and integrity of the ER membrane.
Oxidative stress and impaired ER structure leads to a release of ER calcium which can
initiate cell death pathways such as apoptosis and necrosis.

18

1.4

Eukaryotic Elongation Factor 1A-1 (eEF1A-1)
Eukaryotic elongation factor 1A (eEF1A) was originally identified as a mediator

of aminoacyl-tRNA (aa-tRNA) recruitment to the ribosome during peptide elongation
(McKeehan and Hardesty, 1969). eEF1A is now known to be involved in other cellular
processes such as protein degradation, apoptosis and cytoskeletal organization (Mateyak
and Kinzy, 2010). Mammals express two different isoforms of eEF1A; eEF1A-1 and
eEF1A-2, which are approximately 92% identical at the amino acid level. These two
isoforms are tissue specific and differ in their developmental expression patterns (Kahns
et al., 1998). eEF1A-1 is expressed ubiquitously in mouse and human tissues, however,
eEF1A-2 is only expressed in skeletal muscle, heart and brain (Khalyfa et al., 2001).
eEF1A-1 is the only isoform expressed in liver tissue (Newbery et al., 2007). Both
isoforms function similarly with regards to their role in peptide elongation (Kahns et al.,
1998).

1.4.1 eEF1A-1 and Protein Synthesis
The canonical role of eEF1A-1 is to deliver aa-tRNA to the A site of the ribosome
during elongation allowing for the formation of peptide bonds and the elongation of the
polypeptide (Mateyak and Kinzy, 2010). eEF1A-1 mediated binding and recruitment of
aa-tRNA to the ribosome is guanosine-5-triphosphate (GTP)-dependent. GTP is
hydrolysed to guanosine diphosphate (GDP) after a correct match between the anticodon
stem and the messenger ribonucleic acid (mRNA) codon (Perez and Kinzy, 2014).
Comprising 1-2% of total cellular protein, eEF1A-1 is the second most abundant
eukaryotic protein, after actin (Ejiri, 2002). eEF1A-1 consists of three distinct domains
involved in different aspects of its function. Domain I is the GTP binding domain,
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domain II is involved in the binding of aa-tRNA and domain III is the actin binding
domain (Marco et al., 2004; Mateyak and Kinzy, 2010). We, and others, have shown that
in some cell types, including hepatocytes, skeletal myocytes, enterocytes, and pancreatic
β-cells, eEF1A-1 is primarily localized to the cytosolic compartment associated with the
ER, in particular ribosomes (Chen et al., 2010; Didichenko et al., 1991; Hayashi et al.,
1989; Minella et al., 1996; Stoianov, 2013; Stoianov et al., 2015).

1.4.2 Regulation of the Cytoskeleton by eEF1A-1
In addition to its role in peptide elongation, eEF1A-1 has been to shown to bind
and mediate actin cytoskeleton organization (Yang et al., 1990). Genetic screens have
shown that the specific region of eEF1A-1 actin binding is found in domain III (Gross
and Kinzy, 2005). In some cell types, greater than 60% of eEF1A-1 is estimated to be
associated with the actin cytoskeleton (Gross and Kinzy, 2005). Studies have shown that
eEF1A-1 binds actin, inhibits the rate of actin polymerization and stabilizes actin
filaments (Liu et al., 2002; Liu et al., 1996; Murray et al., 1996). This regulation of the
actin cytoskeleton is mediated through globular actin (G-actin) binding and filamentous
actin (F-actin) bundling activity (Murray et al., 1996). Furthermore, eEF1A-1 has been
shown to bundle, stabilize and sever microtubules under various conditions (Durso and
Cyr, 1994; Gross and Kinzy, 2005; Murray et al., 1996; Shiina et al., 1994).

1.4.3 eEF1A-1 and Cell Death
Several lines of evidence indicate that eEF1A-1 is involved in mediating
apoptosis in response to cell stress. eEF1A-1 expression is induced by oxidative and ER
stress and plays a significant role in mediating apoptosis under both conditions
(Borradaile et al., 2006a; Chen et al., 2000; Lamberti et al., 2004). Studies in mouse
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fibroblasts have shown a correlation between eEF1A-1 protein levels and the onset of
apoptosis during serum induced apoptotic conditions (Duttaroy et al., 1998). In cultured
cardiomyocytes, protein levels of eEF1A-1 increase under H2O2 induced apoptotic
conditions (Chen et al., 2000). Furthermore, it has been reported that a decrease in
eEF1A-1 expression confers resistance to palmitate and H2O2 induced oxidative and ER
stress in CHO cells, cardiomyocytes and hepatocytes (Borradaile et al., 2006a; Stoianov,
2013; Stoianov et al., 2015). eEF1A-1 has also recently been implicated in anoikis, which
is a specific form of apoptosis initiated by a loss of cell anchorage (Itagaki et al., 2012).
Increased membrane levels of eEF1A-1 appear to increase fibroblast susceptibility to
anoikis during serum starvation conditions while disrupting this increase using small
interfering RNA (siRNA) results in cellular resistance to anoikis (Itagaki et al., 2012).
The pro-apoptotic effects of eEF1A-1 expression may partly depend on its interaction
with the cytoskeleton (Borradaile et al., 2006a).

1.4.4 Inhibition of eEF1A-1 Activity with Didemnin B
The structure of eEF1A-1 has been extensively studied and high resolution crystal
structures have been created to provide detailed information about the different domains
of eEF1A-1 (Marco et al., 2004). As mentioned in section 1.4.1, eEF1A-1 has three well
defined domains, each with a different functional role. Didemnin B, a cyclic depsipeptide
produced by marine tunicates (sea squirts), specifically binds GTP-bound eEF1A-1,
between domain I (GTP binding) and domain II (aa-tRNA binding), at the ribosome, and
inhibits peptidyl-tRNA translocation and peptide elongation (Figure 1.3) (Ahuja et al.,
2000; Lee et al., 2012; Marco et al., 2004; Robert et al., 2009). Didemnin B mediated
inhibition of protein synthesis is eEF1A-1 dependent and acts by binding eEF1A-1 and
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Figure 1.3 Binding site of didemnin B in eEF1A-1.
Schematic representation of the structure of eEF1A-1 (red barrels represent α-helices,
yellow flat ribbons represent β-strands, blue arrows represent turns). Didemnin B
specifically binds GTP-bound eEF1A-1 between domain I (GTP binding site) and
domain II (aa-tRNA binding site), represented by the framed area, independent of domain
III (Actin binding site). Adapted from Marco et al.(2004).
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inhibiting its release from the ribosomal A-site (Marco et al., 2004). Didemnin B was the
first marine organism-derived drug to be clinically tested in humans. Clinical trials
applied the inhibitory effects of didemnin B on peptide elongation and protein synthesis
for use as an antitumor and anticancer agent (Potts et al., 2015; Robert et al., 2009; Xu et
al., 2012). The chemotherapeutic activity of didemnin B was first characterized in
leukemia and clinical trials have gone on to document responses in a wide array of solid
tumors, although the mechanism of action of didemnin B is still not completely
understood. Ultimately, didemnin B failed to demonstrate widespread effective antitumor
activity in clinical trials, and was associated with significant intestinal toxicity. However,
a recent report suggests that didemnin B may be effective in a subset of acute
lymphoblastic leukemia (ALL) based on its ability to inhibit both eEF1A-1 and
palmitoyl-protein thioesterase 1 (PPT1) activity (Potts et al., 2015).
Recent work from our lab has determined a role for didemnin B and eEF1A-1 in
hepatocyte lipotoxicity. We have shown that inhibition of the peptide elongation activity
of eEF1A-1 with didemnin B, at non-cytotoxic concentrations, reduces palmitate-induced
cell death in HepG2 cells (a model of human hepatocytes) (Stoianov, 2013; Stoianov et
al., 2015). When these cells were exposed to high palmitate, eEF1A-1 protein was
rapidly, though modestly, induced, and partially re-localized from its predominant
location at the ER to polymerized actin at the cell periphery. This early induction and
subcellular redistribution of eEF1A-1 coincided with the onset of ER stress, and was later
followed by cell death which could be partially blocked by incubation with didemnin B.
These data implicated eEF1A-1 in hepatocyte lipotoxicity (Stoianov, 2013; Stoianov et
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al., 2015). A general model of the role of eEF1A-1 in the pathways involved in
hepatocyte lipotoxic cell death is shown in Figure 1.4.
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Figure 1.4 Working model of the role of eEF1A-1 in the pathways involved in
hepatocyte lipotoxicity.
Excess saturated fatty acids, such as palmitate, can overwhelm the ability of a hepatocyte
to store them as triglycerides (lipid droplets), to catabolise them through β-oxidation in
the mitochondria, and to export them as triglycerides in lipoproteins. This can result in
the production of reactive oxygen species (ROS) which can lead to oxidative and ER
stress. Excess palmitate can also impair the structure and integrity of the ER membrane.
Oxidative stress and impaired ER structure leads to a release of ER calcium which can
initiate cell death pathways. Under basal conditions, eEF1A-1 (green circles) is localized
to the ER. Fatty acid overload, in particular palmitate, results in the mobilization of
eEF1A-1 from the ER to the actin (red circles) cytoskeleton. eEF1A-1 may mediate
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changes in the actin cytoskeleton that are necessary for the progression of cell death
and/or may promote cell death through its protein synthetic activity at the ER.
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1.5

Hepatic Lipotoxicity in Mouse Models of Obesity
Studies of the involvement of hepatic lipotoxicity in NAFLD progression rely on

suitable rodent models of the disease. There are several mouse models of obesity and
NAFLD; however, few of these have the complete set of characteristics associated with
the human disease. Currently, there is no single rodent model that encompasses the full
spectrum of human disease progression (Imajo et al., 2013). There are two different
classifications of rodent models of obesity and NAFLD that are readily available. The
first group includes genetically modified mice in which liver disease and characteristics
of metabolic syndrome develop spontaneously (Imajo et al., 2013). The second group
includes models in which disease is induced through dietary intervention (Imajo et al.,
2013). Each model poses a different set of advantages and disadvantages (Anstee and
Goldin, 2006).

1.5.1 Genetic Models
Leptin-deficient, also known as ob/ob, mice on a C57BL/6J background have a
mutation in the leptin encoding obese (ob) gene on chromosome 6 and therefore lack a
satiety signal (Anstee and Goldin, 2006). Leptin is a 16 kDa adipokine (Anstee and
Goldin, 2006). It is an anorexigenic peptide that acts on the hypothalamic ventral median
nucleus to regulate appetite (Anstee and Goldin, 2006; Kelesidis et al., 2010). The
secretion of leptin from adipose tissue and its binding to leptin receptors expressed in the
brain and peripheral tissues signals satiety and reduces caloric intake (Margetic et al.,
2002). Leptin also mitigates excess ectopic accumulation of lipid in non-adipose tissues
by stimulating fatty acid oxidation (Unger and Scherer, 2010). Ob/ob mice are constantly
in a state of perceived starvation and if given the opportunity will overeat and become
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obese (Anstee and Goldin, 2006). This results in a hyperphagic, hyperinsulinemic and
hyperglycemic phenotype (Nagarajan et al., 2012). Histological characteristics of ob/ob
mice include hepatic lipid deposition and steatosis, and enlarged pancreatic islets of
Langerhans (Anstee and Goldin, 2006). The ob/ob model has increased expression of
TNFα and excess white adipose tissue which promotes adipose tissue lipolysis and the
subsequent flux of free fatty acids to the liver, contributing to the development of hepatic
steatosis (Anstee and Goldin, 2006). SREBP-1c is also activated in the livers of ob/ob
mice leading to increased fatty acid synthase activity and de novo lipogenesis. Ob/ob
mice develop hepatic steatosis and NAFLD spontaneously; however, unlike humans with
NAFLD, they do not progress to NASH. This model requires a secondary insult such as
administration of a methionine and choline deficient diet, or lipopolysaccharide
endotoxin to trigger progression to steatohepatitis (Nagarajan et al., 2012; Takahashi et
al., 2012). The ob/ob model is also protected against fibrosis due to defects in
transforming growth factor (TGF)-β production associated with the C57BL/6J
background (Anstee and Goldin, 2006). This leads to a reduction in TGFβ-dependent
genes such as pro-collagen type 1, resulting in the inhibition of fibrosis (Cheng et al.,
2009; Peverill et al., 2014). Resistance to hepatic fibrosis means that ob/ob mice are not
an accurate model for the study of the end stages of NASH (Basaranoglu and Ormeci,
2014). A counterpart to the ob/ob mouse is the db/db mouse. Db/db mice, on a C57BL/6J
background, have a natural mutation in the diabetes (db) gene on chromosome 4 that
encodes the leptin receptor (Ob-Rb) and results in obesity, dyslipidemia, insulin
resistance, pancreatic β-cell dysfunction and macrovesicular hepatic steatosis (Anstee and
Goldin, 2006; Imajo et al., 2013; Wang et al., 2014a). Db/db mice have normal or
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elevated leptin levels, however; due to the mutation in the leptin receptor they are
resistant to its effects (Nagarajan et al., 2012). Like the ob/ob mouse model, NAFLD in
db/db mice will not progress from hepatic steatosis to NASH, unless provided with a
secondary insult such as administration of a methionine and choline deficient diet
(Takahashi et al., 2012). Both the ob/ob and db/db mouse models develop obesity, insulin
resistance and metabolic syndrome quickly. Thus, there is no need for lengthy feeding
protocols, invasive procedures or surgical interventions (Wang et al., 2014a). They are
also representative of the human presentation of these metabolic conditions (Takahashi et
al., 2012), and are useful for studying the progression through the spectrum of hepatic
lipid accumulation, and the early stages of hepatic lipotoxicity (Anstee and Goldin,
2006).

1.5.2 Diet-induced Models
Diet-induced models of obesity can be time consuming depending on the length
of the feeding protocol required. However, when compared to genetic models of obesity,
they are likely more representative of obesity, metabolic syndrome, and the development
of NAFLD found in the human population.
High fat diets can be used to induce hepatic steatosis and NASH in rodent models.
However, using a diet to induce NAFLD can result in inconsistencies in the degree of
steatosis, inflammation, and fibrosis (Nakamura and Terauchi, 2013). The degree of
induction of these characteristics of metabolic syndrome depends on the rodent strain, the
composition of the diet; in particular the fat content, and the duration of the treatment
(Nakamura and Terauchi, 2013; Takahashi et al., 2012). Choosing the correct rodent
strain is important, as although the majority of rodents become obese on a high fat diet,
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there are often discrepancies in weight, glucose intolerance, insulin resistance, and
dyslipidemia (Fellmann et al., 2013). Long-term exposure to high fat diet has been shown
to consistently induce obesity, insulin resistance and NASH in C57BL/6J mice but does
not produce liver fibrosis (Anstee and Goldin, 2006; Hill-Baskin et al., 2009). A typical
high fat diet consists of a minimum of 60% of calories from fat, an extreme which is not
represented in the diets of human populations of obesity and therefore lacks clinical
significance (Ghibaudi et al., 2002; Johnston et al., 2007). A more relevant diet,
representative of the diet consumed by humans with metabolic syndrome, is the Western
diet- a high fat, high carbohydrate diet, which consists of approximately 40% of calories
from fat (Meek et al., 2010). Western diet, which is representative of the diet consumed
by humans in Westernized countries, induces obesity, insulin resistance and NASH like
the high fat diet described above. However, as a result of its lower fat percentage, much
longer feeding protocols are required to induce significant NAFLD progression
(Basaranoglu et al., 2013; Myles, 2014; Tsuchiya et al., 2012).
Carbohydrate adjusted diets can also be used to induce obesity and NAFLD in
rodents, including C57BL/6J mice (Anstee and Goldin, 2006; Nakamura and Terauchi,
2013). Changes in diets worldwide have led to an increase in the consumption of
processed foods rich in both fat and high fructose corn syrup (Kargulewicz et al., 2014).
Like high fat and Western diets, diets rich in fructose lead to the development of severe
obesity, hyperinsulinemia, hepatic steatosis and glucose intolerance in mice (Imajo et al.,
2013). High fructose diets have also been found to induce oxidative stress and increase
expression of proinflammatory cytokines in the liver, but do not lead to fibrosis or
hepatocellular carcinoma (Imajo et al., 2013). The primary site of fructose metabolism is
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the liver, however, unlike glucose, uptake and metabolism of fructose is not negatively
regulated by phosphofructokinase resulting in increased de novo lipogenesis
(Basaranoglu et al., 2013; Elliott et al., 2002). Furthermore, fructose does not stimulate
insulin or leptin secretion, and prevents the inhibition of the secretion of ghrelin; an
orexigenic peptide, leading to impaired satiety signals and resulting in the obesity and
hepatic steatosis characteristic of high fructose diets (Basaranoglu et al., 2013; Inui,
2001).

1.6

Objectives and Hypothesis

1.6.1 Rationale
eEF1A-1 was initially identified as a mediator of lipotoxic cell death through a
genetic screen. This screen used a ROSAβgeo retroviral promoter trap in CHO cells to
identify factors that, when disrupted, conferred resistance to palmitate-induced cell death
(Borradaile et al., 2006a). Subsequent studies showed that inhibiting eEF1A-1 expression
and/or activity, using either siRNA or chemical inhibition with didemnin B conferred
resistance to palmitate-induced death in cardiomyocytes and in HepG2 cells (Borradaile et
al., 2006a; Stoianov, 2013; Stoianov et al., 2015). Moreover, in vivo, eEF1A-1 expression is
induced in the livers of obese mice with severe hepatic steatosis (Stoianov, 2013; Stoianov et
al., 2015).
The goal of this thesis was to extend these previous studies in cardiomyocytes and
hepatocytes to a mouse model of obesity and NAFLD and to further investigate the effects of
eEF1A-1 inhibition in HepG2 cells.
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1.6.2 Hypothesis
Inhibition of eEF1A-1 peptide elongation activity decreases hepatic ER stress and
lipotoxicity.

1.6.3 Specific Objectives
1. Determine the effect of didemnin B on hepatic lipotoxicity in genetically obese mice
2. Determine the effect of didemnin B on palmitate-induced ER stress and cell death in
HepG2 cells

1.6.4 Relevance to Disease
Metabolic syndrome, obesity, and associated NAFLD are increasing in prevalence
throughout the world, yet little is known about the mechanism responsible for
progression of NAFLD. eEF1A-1 has been identified as a mediator of lipotoxic cell death
in cultured hepatocyte-like cells (Stoianov, 2013; Stoianov et al., 2015). However,
whether eEF1A-1 plays a significant role in hepatocyte lipotoxic responses in vivo is
unknown. A greater understanding of the mechanism of action of eEF1A-1 in lipotoxicity
may provide insight into the progression of this spectrum of liver disease (Figure 1.5).
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Figure 1.5 Progression of nonalcoholic fatty liver disease.
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic
syndrome and represents a spectrum of lipid accumulation in the liver ranging from
benign steatosis to nonalcoholic steatohepatitis (NASH). Metabolic syndrome and the
resulting flux of non-esterified fatty acids (NEFA) from adipose, hypertriglyceridemia,
and de novo lipogenesis lead to hepatic steatosis. Little is known about the causes of
progression of NAFLD. It is unknown if eukaryotic elongation factor 1A-1 (eEF1A-1)
plays a role in the progression of NAFLD to NASH and end stage liver disease. Adapted
from Tailleux et al. (2012).
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Chapter 2

2

Materials and Methods

2.1

Mice
Studies were approved by the Western University Animal Care Committee and

performed in accordance with the Canadian Guide for the Care and Use of Laboratory
Animals. Five-week old male C57BL/6J and leptin-deficient (ob/ob) mice (Jackson
Laboratory, Bar Harbor, ME) were fed ad libitum on AIN-76A semi-purified diet (17.7%
protein, 64.9% carbohydrate, and 5.2% fat by weight) (Harlan Teklad, Indianapolis, IN)
for 4 weeks. During week 5, mice were given intraperitoneal (i.p.) injections of didemnin
B (50 µg/kg) or vehicle control on day 1, 4, and 7. Didemnin B was obtained from the
Open Chemical Repository of the Developmental Therapeutics Program at the National
Cancer Institute (NIH), and solubilized in 1% dimethyl sulfoxide (DMSO), 5.2%
PEG400, 5.2% Tween 80, and 88.6% sterile saline (Robert et al., 2009). Body weight and
food consumption were measured daily and a group of leptin-deficient plus vehicle
control mice were pair-fed to match leptin-deficient plus didemnin B mice for caloric
intake (Figure 2.1).
Prior to sacrifice, glucose tolerance was measured following a 6 h fast and oral
gavage of a 20% solution of D-glucose (BDH Chemicals, United Kingdom) to deliver a
dose of 1 g of glucose/kg body weight. Insulin tolerance was measured following a 6 h
fast and i.p. injection of 0.6 IU of insulin (Novo Nordisk Inc, Denmark) /kg body weight.
Blood glucose levels were measured using an Ascensia Contour glucometer (Bayer
Healthcare, Toronto, ON). Animals were sacrificed using carbon dioxide (CO2). Upon
sacrifice, body weight was recorded, blood was obtained by cardiac puncture, and tissues
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Figure 2.1 Animal experimental model schematic.
Five week old male C57BL/6J and ob/ob mice were fed ad libitum or pair fed on AINAIN
76A semi-purified
purified diet for 4 weeks. During week 5, ob/ob mice were randomly assigned
to either experimental or control groups and given i.p. inj
injections
ections of didemnin B (50
µg/kg)
g/kg) or vehicle control, while C57BL/6J mice were given i.p. injections of vehicle
control, on day 28, 31, and 34. Prior to sacrifice on day 38, glucose tolerance and insulin
tolerance were measured. Upon sacrifice, blood and ti
tissue
ssue was collected for post-mortem
post
analyses of gross histological determinations of morphology and lipid content, and for
biochemical determinations of specific lipid species and specific protein contents.
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were harvested, weighed and processed for gross histological determinations of
morphology and lipid content, and for biochemical determinations of specific lipid
species and specific protein contents.

2.2

Cell Culture
HepG2 cells were obtained from the American Type Culture Collection

(Rockville, MD). HepG2 human hepatoma cells, like normal human and rodent liver,
exclusively express the eEF1A-1 variant of eEF1A (Grassi et al., 2007; Newbery et al.,
2007). This characteristic is not shared by other, less-differentiated cell lines including
JHH6, HuH7, and rat McArdle RH-7777 (Grassi et al., 2007). Also, like normal human
liver, HepG2 cells exclusively secrete full-length apoB100 which responds to
physiological stimuli such as insulin and oleate. Cells were grown on 100 mm culture
dishes at 37°C and 5% CO2 and maintained in 10 ml of Eagles minimum essential
medium (EMEM) (Lonza Biowhittaker, Basel, Switzerland) supplemented with 10%
fetal bovine serum (FBS), 50 IU/ml penicillin, 50 µg/ml streptomycin, 0.5 µg/ml
fungizone and 2 mM L-glutamine (Life Technologies, Carlsbad, CA). Cells were split
(1:6-1:8) every 7 days using trypsin-EDTA. For experiments, cells were plated in 6-well
(35 mm), or 24-well (15.5 mm) culture plates (Greiner Bio-One, Monroe, NC).
For fatty acid treatments, media was supplemented with 1.0 mM palmitate. Fatty
acids were prepared by heating a 20 mM solution of palmitate in 0.02 M NaOH at 70°C
for 30 minutes. Solubilization of fatty acids was facilitated by adding 1 N NaOH
dropwise. Fatty acids were complexed to 30% fatty acid free BSA (Sigma-Aldrich, St.
Louis, MO) at a fatty acid to BSA ratio of 2:1 and then added to cell culture media. BSANaOH supplemented media was used as a control. A 1.0 mM fatty acid concentration was
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used to reflect the high physiological and pathophysiological conditions tissues are
exposed to during obesity and metabolic syndrome (Soriguer et al., 2009).

2.3

Liver Histology
For analyses of liver tissue morphology and lipid droplet content in C57BL/6J and

ob/ob mice, liver samples were embedded in optimal cutting temperature compound
(OCT) (Sakura Finetek USA, Inc, Torrance CA) at the time of sacrifice. Hepatic sections
(8 µm) were prepared with a cryostat (Leica Biosystems, Germany) and stained with
either hematoxylin and eosin (H&E) (Leica Biosystems, Germany) or Oil Red O (ORO)
(Sigma-Aldrich, St. Louis, MO). Sections were imaged using an inverted Olympus BX51
microscope using 10X, 20X and 40X objectives.

2.4

Liver Lipids
Total liver lipids were extracted using the Folch method (Folch et al., 1957), from

samples frozen in liquid nitrogen and subsequently stored at -80°C. Triglycerides, free
cholesterol, and total cholesterol from chloroform extracts of liver tissue were determined
by enzymatic, colorimetric assays using reagents from Roche Diagnostics (Laval, QC)
for triglyceride assays and reagents from Wako Diagnostics (Richmond, VA) for free
cholesterol and total cholesterol assays (Assini et al., 2013). All plasma and liver lipid
measurements were performed through the Metabolic Phenotyping Laboratory in Robarts
Research Institute.

2.5

Plasma Insulin, Plasma Lipids, and Plasma Liver Enzymes
Plasma insulin was measured using ultrasensitive mouse-specific enzyme-linked

immunosorbent assays (ELISA) (Alpco Diagnostics, Windham, NH) (Assini et al., 2013).
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Plasma triglyceride, total cholesterol and free fatty acid concentrations from C57BL/6J
and ob/ob mice were measured via enzymatic, colorimetric assays using reagents
obtained from Roche Diagnostics (Laval, QC). Plasma AST and ALT, markers of hepatic
cell injury (Sanyal, 2002), were measured using enzymatic rate assays by the London
Health Sciences Centre Core Laboratory.

2.6

Fast Performance Liquid Chromatography Profiles of Plasma
Lipoproteins
Plasma lipoprotein distribution in C57BL/6J and ob/ob mice was determined by

Fast Performance Liquid Chromatography (FPLC) using a modified method previously
described by Assini et al. (2013). Fresh EDTA plasma (50 µl) was separated by FPLC
using an AKTA purifier and a Superose 6 column. A constant flow rate of 0.4 ml/minute
was used to collect 750 µl fractions. A 125 µl aliquot of each fraction was used to
measure total cholesterol and triglyceride enzymatically in samples on a 96 well
microtitre plate with 75 µl of two times concentrated reagents (triglyceride, Roche
Diagnostics, Laval, QC; cholesterol, Wako Diagnostics, Richmond, VA; standards,
Randox, Crumlin, Co. Antrim, United Kingdom).

2.7

Immunoblot Analyses
For analyses of hepatic protein expression in mice, livers were harvested, snap

frozen in liquid nitrogen, and tissue homogenates were prepared using a WHEATON
tissue homogenizer (WHEATON, Millville, NJ) and drill in radioimmunoprecipitation
assay (RIPA) buffer (150mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium
deoxycholate, 0.1% SDS, and 50 mM Tris-HCl, pH 8.0) containing protease and
phosphatase inhibitors (protease inhibitors, Roche Diagnostics, Laval, QC; RIPA,
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phosphatase inhibitors, Sigma-Aldrich, St. Louis, MO). Homogenates were centrifuged
for 2 minutes at 14,000 rpm to remove insoluble debris. Total protein in the supernatants
was quantified using the Pierce Bicinchoninic Acid (BCA) Protein Assay Kit (Thermo
Scientific, Rockford, IL). Aliquots containing 75-100 µg were diluted 1:1 with 2X
Laemmli sample buffer (LSB) (Bio-Rad, Hercules, CA) and heated to 100ºC for 5
minutes. Samples were resolved using a Mighty Small II Mini Vertical Electrophoresis
System (Hoefer Inc., Holliston, MA) and Pierce Precise 10% SDS-polyacrylamide gel
electrophoresis (PAGE) (Thermo Scientific, Rockford, IL). Samples were then
transferred to a 0.45 µm Amersham Hybond polyvinyl difluoride (PVDF) membrane (GE
Healthcare Life Sciences, United Kingdom) using the Panther Semi-Dry Electroblotter
transfer apparatus (OWL Scientific Inc., Thermo Scientific, Rockford, IL). Membranes
were incubated in 5% BSA (Millipore, Billerica, MA) in Tris-Buffered Saline, 0.1%
Tween-20 (Bio-Rad, Hercules, CA) (TBS-T) blocking buffer for 1 h. To detect
eukaryotic elongation factor 1A-1 (eEF1A-1), membranes were incubated overnight at
4ºC with a 1:1000 dilution of anti-eEF1A-1 rabbit polyclonal antibody (Cell Signaling
Technology, Danvers, MA), and then a 1 h incubation with a 1:5000 dilution of a
horseradish peroxidase (HRP)-conjugated polyclonal anti-rabbit antibody (Santa Cruz
Biotechnology, Dallas, TX). Phosphorylated eukaryotic translation initiation factor 2α
(eIF2α) was detected following an overnight incubation with a 1:250 dilution of antiphospho-eIF2α rabbit monoclonal antibody (Cell Signaling Technology, Danvers, MA)
and a 1 h incubation with a 1:5000 dilution of HRP-conjugated polyclonal anti-rabbit
antibody (Santa Cruz Biotechnology, Dallas, TX). eIF2α was detected following an
overnight incubation with a 1:1000 dilution of anti-eIF2α rabbit polyclonal antibody
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(Cell Signaling Technology, Danvers, MA) and a 1 h incubation with a polyclonal antirabbit HRP secondary antibody. Binding immunoglobulin protein (BiP), also known as
78 kDa glucose-regulated protein (GRP78), was detected following an overnight
incubation with a 1:500 dilution of anti-GRP78 rabbit polyclonal antibody (Cell
Signaling Technology, Danvers, MA) and a 1 h incubation with a polyclonal anti-rabbit
HRP secondary antibody. Phosphorylated c-Jun-N-terminal kinase (JNK) was detected
following an overnight incubation with a 1:250 dilution of anti-phospho-JNK rabbit
monoclonal antibody (Cell Signaling Technology, Danvers, MA) and a 1 h incubation
with a 1:5000 dilution of HRP-conjugated polyclonal anti-rabbit antibody. JNK was
detected following an overnight incubation with a 1:1000 dilution of anti-JNK rabbit
polyclonal antibody (Cell Signaling Technology, Danvers, MA) and a 1 h incubation with
a polyclonal anti-rabbit HRP secondary antibody. Actin was detected following an
overnight incubation with a 1:5000 dilution of anti-actin rabbit polyclonal antibody
(Sigma-Aldrich, St. Louis, MO) and a 1 h incubation with a polyclonal anti-rabbit HRP
secondary antibody. After subsequent incubations with primary and secondary
antibodies, membranes were washed 3 times for 5 minutes with TBS-T. Membranes were
then incubated with BM Chemiluminescence Western Blotting Substrate (POD) (Roche
Diagnostics, Laval, QC) for 1 minute and exposed on Amersham Hyperfilm (GE
Healthcare Life Sciences, United Kingdom). Bands corresponding to eEF1A-1 ran beside
the 50 kDa reference band of the Precision Plus Protein All Blue Standards (Bio-Rad,
Hercules, CA). Bands corresponding to phospho-eIF2α and eIF2α ran at 38 kDa. Double
bands corresponding to phospho-JNK and JNK ran as a doublet at 46 and 54 kDa, while
bands corresponding to GRP78 and actin ran at 78 kDa and 42 kDa, respectively. All
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bands were quantified by densitometry using Quantity One 1-D Analysis Software (BioRad, Hercules, CA) and normalized to actin. Phosphorylated protein was normalized to
total corresponding protein.
For analyses of protein expression in HepG2 cells following treatments with fatty
acids in the absence or presence of didemnin B, whole cell lysates were prepared using
RIPA buffer supplemented with protease and phosphatase inhibitors. GRP78, actin,
eIF2α and phosphorylated eIF2α protein levels from lysates (20-50 µg) were determined
by immunoblotting as described above. Bands were quantified by densitometry and
normalized to actin. Phosphorylated protein was normalized to total corresponding
protein.

2.8

[3H] Leucine Incorporation Assays
For time course experiments using didemnin B, HepG2 cells were plated in 24-

well plates and grown to 70-80% confluency. Cells were treated with 250 µl of palmitate
supplemented media, or BSA control media, and 80 nM of didemnin B or DMSO as a
control for 6, 16 and 24 h. Following pre-treatment, 0.25 µCi of L-[4, 5-3H] leucine was
added to each well. Cells were incubated at 37°C for 60 minutes and then media was
removed. RIPA buffer was added to each well and incubated on ice for 30 minutes.
Media was centrifuged at 1000 rpm for 5 minutes at 4°C and the supernatant (secreted
protein) was precipitated with cold trichloroacetic acid (TCA) for 60 minutes. The RIPA
buffer cell digest was added to the pellet (non-secreted protein) and precipitated with cold
TCA for 60 minutes. A sample from the RIPA buffer cell digest was taken, prior to
precipitation, for total protein quantification using the BCA Protein Assay Kit. Samples
were centrifuged at 12,000 rpm for 2 minutes at 4°C and washed 3 times in 100% ethanol
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by resuspension and centrifugation. The pellet was then solubilized in 100 µl 1N NaOH
and left overnight at room temperature. Samples were prepared using Ecoscint H
scintillation fluid (National Diagnostics, Atlanta, GA) and counted using a Beckman
Coulter LS6500 Multipurpose Scintillation Counter (Beckman Coulter, Brea, CA).
To determine the IC50 of didemnin B and cycloheximide (Sigma-Aldrich, St.
Louis, MO) for inhibition of protein synthesis, HepG2 cells were plated in 24-well plates
and grown to 70-80% confluency. Cells were treated with increasing concentrations of
didemnin B (up to 200 nM) or cycloheximide (up to 500 nM) for 48 h. Following
treatment, 0.25 µCi of L-[4, 5-3H] leucine was added and the wells were incubated for 60
minutes. Cells were prepared and counted as described above with the exception of the
separation of media and supernatant. Media and supernatant were combined and counts
measured represented the amount of [3H] leucine incorporated into newly synthesized
protein, and were expressed relative to total protein for each sample.

2.9

Cell Death
Cell death and apoptosis were assessed by the Dead Cell Apoptosis Kit

(Molecular Probes, Eugene, OR) using Alexa Fluor 488 annexin V to stain for apoptosis
and propidium iodide (PI) to identify membrane permeability. HepG2 cells were pretreated for 30 minutes with the previously determined IC50 of didemnin B (80 nM) or
cycloheximide (50 nM) and then treated with fatty acid media with or without didemnin
B or cycloheximide for 48 h. Following 48 h incubations, cells were washed in cold
phosphate-buffered saline (PBS) and harvested by trypsinization. Cells were centrifuged
and re-suspended in annexin-binding buffer at a density of 1 x 106 cells/ml. A 100 µg/ml
working solution of PI was prepared by diluting 1 mg/ml PI stock solution in 45 µl of
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annexin-binding buffer. Cells were stained with 5 µl of Alexa Fluor 488 annexin V and 1
µl of PI working solution and incubated on ice for 15 minutes in the dark. Samples were
analysed via flow cytometry, with quantification of 104 cells/sample. Fluorescence
emission was measured at 530 nm and >575 nm using 488 nm excitation. Dead cells
were defined as PI positive or annexin V positive and PI positive. Apoptotic cells were
defined as annexin V positive and PI negative. Live cells were negative for both annexin
V and PI.

2.10 Statistical Analyses
Statistical analyses were performed using a Student’s t-test or a one-way ANOVA
followed by Tukey’s post hoc test. Data were displayed as means ± SEM and were
considered statistically significant at p<0.05. GraphPad Prism version 6.0 software was
used for statistical analyses and generation of graphs.
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Chapter 3

3

Results

3.1

Didemnin B Treatment Reduces Food Consumption in Obese
Mice
eEF1A-1 was previously identified as a mediator of lipotoxic cell death in vitro in

hepatocytes, and was found to participate in this process downstream of ER stress
(Stoianov, 2013; Stoianov et al., 2015). Furthermore, we have shown that eEF1A-1
protein is increased in the livers of ob/ob mice with severe hepatic steatosis (Stoianov,
2013; Stoianov et al., 2015). Since ER stress is implicated in the pathogenesis of NAFLD
(Fuchs and Sanyal, 2012), we investigated whether chemical inhibition of eEF1A-1
activity could improve hepatic lipotoxicity in a mouse model of obesity and metabolic
syndrome. For this study, five-week old male C57BL/6J (lean control) and leptin
deficient ob/ob mice were fed AIN-76A diet for 4 weeks. During week 5, mice were
given i.p. injections of didemnin B (50 µg/kg) or vehicle control on day 1, 4, and 7. Pilot
studies revealed that ob/ob mice treated with didemnin B consumed less food than ob/ob
animals treated with vehicle control; therefore, a group of ob/ob mice treated with vehicle
control were pair-fed to match ob/ob mice treated with didemnin B (Figure 3.1). As
expected, body weight and epididymal fat weight were significantly increased in all
ob/ob animals compared to lean control animals (Table 3.1). Neither treatment with
didemnin B, nor caloric restriction affected body weight or epididymal fat weight over
the course of the experiment (Table 3.1).
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Figure 3.1 Didemnin B treatment reduces food consumption in obese mice.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Food consumption
of C57BL/6J (WT), ob/ob, and ob/ob + didemnin B (DB) mice was monitored during
week 5. A group of ob/ob mice (ob/ob + CR) were pair fed to match the caloric intake of
ob/ob + DB mice. Data are expressed as means ± SEM, values with different lower case
letters are significantly different at p<0.05, n=8-12.
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Table 3.1 Morphometric parameters of metabolic disease in obese mice treated with
didemnin B.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed (ob/ob +
Caloric Restriction) on AIN-76A semi-purified diet for 4 weeks. During week 5, mice
received 3 i.p. injections of either vehicle or didemnin B (50 µg/kg), as indicated, every
third day. Body weight and epididymal fat weight were determined at sacrifice (day 38).
Data are expressed as means ± SEM, values with different lower case letters are
significantly different at p<0.05, n=8-12.

47

48

3.2

Didemnin B Treatment Reduces Hepatic Lipid Content in
Obese Mice
Gross morphology and lipid droplet content of hepatic tissues were assessed by

H&E and Oil Red O staining, and light microscopy. As expected, Oil Red O stained liver
tissue sections from ob/ob mice showed increased lipid droplet size compared to sections
from lean control mice. Interestingly, liver tissues from mice treated with didemnin B
showed a dramatic reduction in the overall appearance of lipid droplets, while caloric
restriction resulted in regional reversion of hepatic steatosis (Figure 3.2). We did not
observe fibrosis in the livers of any of the mice in the four experimental groups. Liver
weight was decreased 1.3-fold in both didemnin B and calorie restricted animals,
compared to ob/ob vehicle control mice (Figure 3.3 A). These changes in liver weight
were associated with significant changes in liver lipid contents which, with the notable
exception of cholesteryl esters, were similar for didemnin B treated and calorie restricted
mice. Liver triglyceride levels were decreased 1.5-fold, while liver cholesterol ester
levels were increased 1.5-fold in didemnin B treated mice compared to ob/ob vehicle
control mice (Figure 3.3 B, C). No difference in liver free cholesterol levels was observed
amongst ob/ob vehicle control and treatment groups (Figure 3.3 D).
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Figure 3.2 Treatment of obese mice with didemnin B decreases appearance of liver
steatosis.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Upon sacrifice
(day 38), liver tissues from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob
+ calorie restricted (CR) mice were harvested, embedded in OCT, sectioned, and stained
with either (A) H&E to visualize tissue morphology and inflammatory infiltrates or (B)
Oil Red O to visualize lipid droplets. Scale bar represents 100 µm.

50

51

Figure 3.3 Effects of didemnin B treatment on hepatic lipid contents in obese mice.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Upon sacrifice
(day 38), liver tissues from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob
+ calorie restricted (CR) mice were harvested and liver weight (A) was measured. Tissues
were frozen in liquid nitrogen and triglyceride (TG) (B), cholesterol ester (CE) (C), and
free cholesterol (FC) (D) concentrations were measured in Folch extracts using standard
enzymatic, colorimetric assays. Data are expressed as means ± SEM, values with
different letters are significantly different at p<0.05, n=8-12.
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3.3

Didemnin B Treatment Improves Plasma Lipid Profiles in
Obese Mice
Severe hepatic steatosis and the progression of NAFLD is associated with

impaired ability of the liver to export triglyceride-rich lipoproteins (VLDL) (Camus et al.,
1988; Coenen et al., 2007; Li et al., 1997; Wiegman et al., 2003). Consistent with this
early work, plasma triglycerides were decreased in ob/ob mice compared to lean control
mice (Figure 3.4 A). However, plasma triglycerides were normalized to lean control
levels in didemnin B and calorie restricted animals. Plasma free fatty acid levels were
unchanged between experimental groups (Figure 3.4 B). Interestingly, plasma cholesterol
levels were normalized in didemnin B treated mice, but not in calorie restricted mice
(Figure 3.4 C). Consistent with these plasma lipid data, plasma lipoprotein profiles for
VLDL and LDL were normalized by didemnin B treatment, while caloric restriction only
improved plasma VLDL (Figure 3.5).
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Figure 3.4 Treatment of obese mice with didemnin B normalizes plasma lipids.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Plasma
triglyceride (A), free fatty acids (FFA) (B) and cholesterol (C) were measured in
C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob + calorie restricted (CR)
mice using standard enzymatic, colorimetric assays. Data are expressed as means ± SEM,
values with different letters are significantly different at p<0.05, n=8-12.
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Figure 3.5 Treatment of obese mice with didemnin B normalizes plasma lipoprotein
profiles.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Very low density
lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL)
triglyceride (A) and cholesterol (B) concentrations were measured in eluted fractions of
plasma from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob + calorie
restricted (CR) mice, n=4 mice/group.
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3.4

Didemnin B Treatment Improves Markers of Hepatic
Lipotoxicity in Obese Mice
Hepatic lipotoxicity in mouse models of NAFLD is associated with increased

circulating levels of the liver enzymes ALT and AST, which escape to the circulation
from damaged hepatocytes (Tsutsumi et al., 2011). Plasma ALT levels in didemnin B
treated mice and calorie restricted mice were decreased 2.4 and 1.9-fold, respectively,
compared to ob/ob vehicle control mice. Similarly, plasma AST levels were decreased
2.3 and 2.0-fold in didemnin B treated and calorie restricted animals, respectively,
compared to ob/ob vehicle control mice (Figure 3.6). These data suggest that didemnin B
can improve NAFLD-associated liver damage, but that this effect may be mostly due to
reduced food intake in these mice.
ER stress is known to be associated with the progression of NAFLD in mice
(Zhou and Liu, 2014). Thus, markers of the UPR and ER stress response were assessed in
all experimental groups. No statistically significant differences in hepatic eEF1A-1 and
phosphorylated eIF2α protein expression were observed between groups (Figure 3.7,
Figure 3.8). However, there were trends for increased eEF1A-1 protein expression and
eIF2α phosphorylation in ob/ob mice compared to lean control mice. Moreover,
didemnin B treatment and caloric restriction appeared to decrease eEF1A-1 expression
and eIF2α phosphorylation. Liver GRP78 and phosphorylated JNK expression were
decreased 2.1 and 1.6-fold respectively, in didemnin B treated mice compared to ob/ob
vehicle control mice (Figure 3.9, Figure 3.10). Taken together, these data suggest that
although didemnin B treatment did not inhibit the initiation of ER stress and induction of
the UPR as indicated by the phosphorylation of eIF2α (an early marker of ER stress), it
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did contribute to a reduction in the later phases of the ER stress response as indicated by
decreased upregulation of GRP78 and decreased JNK phosphorylation.
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Figure 3.6 Effects of didemnin B treatment on plasma ALT and AST levels in obese
mice.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Plasma ALT and
AST were measured in C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob +
calorie restricted (CR) mice using enzymatic rate assays. Data are expressed as means ±
SEM, values with different letters are significantly different at p<0.05, n=8-12. Capital
letters are compared to each other while lower case letters are compared to other lower
case letters.
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Figure 3.7 Hepatic eEF1A-1 protein is unchanged in obese mice treated with
didemnin B.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Upon sacrifice
(day 38), liver tissues from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob
+ calorie restricted (CR) mice were harvested and eEF1A-1 protein (50 kDa) was
detected in whole tissue homogenates. eEF1A-1 protein was detected by immunoblotting
and quantified by densitometry. Data are expressed relative to actin. Representative blots
are shown. Data are expressed as means ± SEM, n=8-12.
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Figure 3.8 Phosphorylation of hepatic eIF2α
α protein remains unchanged in obese
mice treated with didemnin B.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Upon sacrifice
(day 38), liver tissues from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob
+ calorie restricted (CR) mice were harvested and phosphorylated eIF2α (P-eIF2α) and
eIF2α protein (38 kDa) were detected in whole tissue homogenates. P-eIF2α and eIF2α
protein were detected by immunoblotting and quantified by densitometry. Data are
expressed relative to total corresponding protein. Representative blots are shown. Data
are expressed as means ± SEM, n=8-12.
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Figure 3.9 Hepatic GRP78 protein is decreased in obese mice treated with didemnin
B.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Upon sacrifice
(day 38), liver tissues from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob
+ calorie restricted (CR) mice were harvested and GRP78 protein (78 kDa) was detected
in whole tissue homogenates. GRP78 protein was detected by immunoblotting and
quantified by densitometry. Data are expressed relative to actin. Representative blots are
shown. Data are expressed as means ± SEM, values with different letters are significantly
different at p<0.05, n=8-12.
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Figure 3.10 Phosphorylation of hepatic JNK protein is decreased in obese mice
treated with didemnin B.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Upon sacrifice
(day 38), liver tissues from C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob
+ calorie restricted (CR) mice were harvested and phosphorylated JNK (P-JNK) and JNK
protein (doublet at 46 and 54 kDa) were detected in whole tissue homogenates. P-JNK
and JNK protein were detected by immunoblotting and quantified by densitometry. Data
are expressed relative to total corresponding protein. Representative blots are shown.
Data are expressed as means ± SEM, values with different letters are significantly
different at p<0.05, n=8-12.
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3.5

Didemnin B Treatment Improves Glucose Homeostasis in
Obese Mice through Decreased Food Intake
Hepatic lipotoxicity is thought to contribute to insulin resistance and disrupted

glucose homeostasis during NAFLD (Tessari et al., 2009). Therefore, parameters of
glucose homeostasis were measured in all experimental groups. Fasting blood glucose
levels at the time of sacrifice were decreased 1.7 and 1.6-fold in didemnin B and calorie
restricted animals respectively, compared to ob/ob vehicle control mice (Figure 3.11).
Oral glucose tolerance was improved in both didemnin B and calorie restricted mice
(Figure 3.12). Plasma insulin levels were decreased 2.2 and 2.1-fold in didemnin B and
calorie restricted animals respectively, compared to ob/ob vehicle control mice (Figure
3.13). No statistically significant differences in insulin tolerance were observed between
groups (Figure 3.14). These data suggest that improvements in glucose homeostasis
observed in mice treated with didemnin B can be completely explained by their decreased
food consumption.
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Figure 3.11 Effects of didemnin B treatment on fasting blood glucose in obese mice.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Prior to sacrifice,
animals were fasted for 6 hours and blood glucose levels were measured in C57BL/6J
(WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob + calorie restricted (CR) mice using
an Ascenia Contour glucometer. Data are expressed as means ± SEM, values with
different letters are significantly different at p<0.05, n=8-12.
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Figure 3.12 Effects of didemnin B treatment on glucose tolerance in obese mice.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Prior to sacrifice,
glucose tolerance (A) was measured in C57BL/6J (WT), ob/ob, ob/ob + didemnin B
(DB), and ob/ob + calorie restricted (CR) mice following a 6 h fast and oral gavage of 1 g
of glucose/kg of body weight. Areas under the curve (AUC) were calculated from data in
A (B). Data are expressed as means ± SEM, values with different letters are significantly
different at p<0.05, n=8-12.
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Figure 3.13 Effects of didemnin B treatment on plasma insulin levels in obese mice.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Prior to sacrifice,
animals were fasted for 6 hours and plasma insulin levels were measured in C57BL/6J
(WT), ob/ob, ob/ob + didemnin B (DB), and ob/ob + calorie restricted (CR) mice using
ultrasensitive mouse-specific ELISA. Data are expressed as means ± SEM, values with
different letters are significantly different at p<0.05, n=8-12.
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Figure 3.14 Effects of didemnin B treatment on insulin tolerance in obese mice.
Five week old C57BL/6J and ob/ob mice were maintained ad libitum or pair fed on AIN76A semi-purified diet for 4 weeks. During week 5, mice received 3 i.p. injections of
either vehicle or didemnin B (50 µg/kg), as indicated, every third day. Prior to sacrifice,
insulin tolerance (A) was measured in C57BL/6J (WT), ob/ob, ob/ob + didemnin B (DB),
and ob/ob + calorie restricted (CR) mice following a 6 h fast and i.p. injection of 0.6 IU
of insulin/kg of body weight. Areas under the curve (AUC) were calculated from data in
A (B). Data are expressed as means ± SEM, values with different letters are significantly
different at p<0.05, n=8-12.
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Together, these studies in mice show that didemnin B treatment modestly
decreases food intake without overt evidence of illness, and improves parameters
associated with hepatic lipotoxicity. Liver triglycerides, plasma cholesterol, plasma ALT
and AST, protein markers of ER stress, fasting blood glucose, and plasma insulin were
decreased. Of these observations, only decreased plasma liver enzymes and improved
glucose homeostasis could be completely attributed to reduced food intake.

3.6

Didemnin B Decreases Palmitate-Induced ER Stress and Cell
Death in Cultured Hepatocytes by Inhibiting eEF1A-1
Protein Synthetic Activity
Having determined the effect of didemnin B on hepatic lipotoxicity in genetically

obese mice, we set out to further characterize the mechanism for inhibition of palmitateinduced cell death by didemnin B in an in vitro model. In this study we used HepG2
human hepatoma cells because, like human and rodent liver, and unlike other hepatocyte
cell lines, they exclusively express the eEF1A-1 isoform of eEF1A (Grassi et al., 2007).
First, the IC50 values for protein synthesis for didemnin B and cycloheximide were
determined by incorporation of [3H] leucine into newly synthesized proteins (Figure
3.15A). Cycloheximide was used as a control in some subsequent experiments because it
inhibits protein synthesis through a mechanism completely independent of eEF1A-1
(Schneider-Poetsch et al., 2010). The IC50 of didemnin B was determined to be 80 nM
whereas the IC50 of cycloheximide was determined to be 50 nM. Cells were then treated
with 1.0 mM palmitate, with or without 50 nM cycloheximide or 80 nM of didemnin B,
for 48 h followed by assessment of cell death by flow cytometry. Treatment of HepG2
cells with palmitate in the presence of didemnin B decreased palmitate induced cell

80

death; however, treatment with cycloheximide had no effect (Figure 3.15 B), suggesting
that protection from palmitate induced cell death was specific to eEF1A-1 inhibition.
To determine whether didemnin B limits the burden of protein synthesis during
fatty acid overload, thereby potentially alleviating ER stress, incorporation of [3H]
leucine into cellular protein was measured with and without the addition of didemnin B
over a time course of exposure to growth medium supplemented with 1.0 mM palmitate.
At the end of each time point, radiolabel was added for 1 h, followed by precipitation of
total cellular proteins with TCA. Consistent with the onset of ER stress, palmitate
significantly decreased protein synthesis at 6 h. However, protein synthetic activity
recovered to approximately 75% of control levels by 24 h (Figure 3.16). This was not the
case for cells treated with didemnin B, which exhibited sustained suppression of protein
synthesis up to 24 h. Consistent with these protein synthesis data, the onset of ER stress
in response to palmitate (as assessed by eIF2α phosphorylation) was not affected by
incubation with didemnin B (Figure 3.17). However, didemnin B did prevent
upregulation of GRP78 protein in response to palmitate (Figure 3.18), suggesting that
inhibition of eEF1A-1 diminishes the later stages of ER stress during which protein
production is re-established, further increasing the burden on this organelle (Krokowski
et al., 2013; Stoianov, 2013; Stoianov et al., 2015). This could prevent subsequent cell
death, as observed with didemnin B in Figure 3.15 B, by allowing the ER to recover and
restore homeostasis.
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Figure 3.15 Decreased palmitate induced cell death is selective for inhibition of
eEF1A-1 dependent protein synthesis.
HepG2 cells were treated for 48 h with increasing concentrations of didemnin B (DB)
(eEF1A-1 elongation function inhibitor), cycloheximide (CHX) (inhibitor of protein
synthesis independent of eEF1A-1 activity), or DMSO as a control, followed by
assessment of total protein synthesis by [3H] leucine incorporation (A). The IC50 for
protein synthesis with didemnin B was 80 nM, the IC50 for protein synthesis with
cycloheximide was 50 nM. HepG2 cells were incubated for 48 h with growth media
containing BSA or 1.0 mM palmitate (PA) conjugated to BSA at a molar ratio of 2:1, in
the presence or absence of 80 nM didemnin B (IC50) or 50 nM cycloheximide (IC50).
Cells were harvested and stained with annexin V (Ann V) and PI and the proportions of
live cells (Ann V- PI-), apoptotic cells (Ann V+ PI-) and dead cells (Ann V+ PI+) were
determined by flow cytometry (B). For A, data are expressed as percentages of control
(vehicle) ± SEM, n=3. For B, data are expressed as means ± SEM, values with different
letters are significantly different at p<0.05, n=4.
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Figure 3.16 Inhibition of eEF1A-1 elongation function suppresses protein synthesis
during saturated fatty acid overload.
HepG2 cells were incubated for 6, 16 and 24 h with growth media containing BSA or 1.0
mM palmitate (PA) conjugated to BSA at a molar ratio of 2:1, in the presence or absence
of 80 nM didemnin B (DB) or DMSO as a control, followed by assessment of total
protein synthesis by [3H] leucine incorporation. Data are expressed as means ± SEM,
values with different letters are significantly different at p<0.05 within time points, n=5.

84

85

Figure 3.17 Didemnin B does not prevent phosphorylation of eIF2α
α protein during
saturated fatty acid overload in HepG2 cells.
HepG2 cells were incubated for 6 h with growth media containing BSA or 1.0 mM
palmitate (PA) conjugated to BSA at a molar ratio of 2:1, in the presence or absence of
80 nM didemnin B (DB) or DMSO as a control. Phosphorylated (P-eIF2α) and total
eIF2α protein (38 kDa) were detected in whole cell lysates by immunoblotting. Bands
were quantified by densitometry and normalized to total eIF2α. Representative blots are
shown. Data are expressed as means ± SEM, *p<0.05, n=4.
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Figure 3.18 Didemnin B prevents GRP78 protein upregulation during saturated
fatty acid overload in HepG2 cells.
HepG2 cells were incubated for 6 h with growth media containing BSA or 1.0 mM
palmitate (PA) conjugated to BSA at a molar ratio of 2:1, in the presence or absence of
80 nM didemnin B (DB) or DMSO as a control. GRP78 protein (78 kDa) was detected in
whole cell lysates by immunoblotting. Bands were quantified by densitometry and
normalized to actin. Representative blots are shown. Black vertical lines on the blots
indicate that lanes from the same blot were re-ordered for presentation purposes. Data are
expressed as means ± SEM, *p<0.05, n=4.

88

89

Chapter 4

4

Discussion

4.1

Summary of Results
The prevalence of NAFLD has increased dramatically over the past several

decades with as much as 30% of the population of the western world now affected
(Schwenger and Allard, 2014; Tuyama and Chang, 2012). Remarkably, this prevalence
rises to 75-80% in obese patients, making NAFLD one of the most common liver
diseases in developed countries (Tuyama and Chang, 2012). Despite the pervasiveness of
NAFLD, little is known about the pathogenesis of this disease. Based on previous
findings identifying eEF1A-1 as a mediator of lipotoxicity in CHO cells, cardiomyocytes,
and hepatocytes, a role for this protein in lipotoxic disease in vivo, in a mouse model of
obesity and NAFLD, was proposed (Borradaile et al., 2006a; Stoianov, 2013; Stoianov et
al., 2015). For this thesis it was hypothesized that inhibition of eEF1A-1 peptide
elongation activity would decrease hepatocyte ER stress and lipotoxicity in the livers of
obese mice. A series of studies revealed several key findings: 1) Treatment of obese mice
with didemnin B, a specific chemical inhibitor of eEF1A-1 peptide elongation function,
modestly decreased food intake without overt evidence of illness; 2) Didemnin B
treatment reduced liver triglycerides, protein markers of ER stress, plasma ALT and
AST, fasting blood glucose, plasma insulin, and plasma cholesterol. Of these
observations, only decreased plasma liver enzymes and improved glucose homeostasis
could be completely attributed to reduced food intake. 3) Specific inhibition of the
elongation function of eEF1A-1 with didemnin B in hepatocytes reduced palmitateinduced ER stress and cell death. Taken together, these findings support the conclusion
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that inhibition of eEF1A-1 activity with didemnin B improved characteristics of hepatic
ER stress and lipotoxicity in obese mice with NAFLD.

4.2

Didemnin B Treatment Reduces Food Consumption in Obese
Mice
Our data from a genetic mouse model of obesity indicate that treatment with

didemnin B leads to a reduction in food consumption with no overt evidence of illness or
toxicity, and no decreases in body weight or fat pad mass over the treatment period (10
days). Didemnin B is a cyclic depsipeptide (Marco et al., 2004), and due to its size it is
unable to cross the blood brain barrier. Therefore, we hypothesize that the observed
reduction in food consumption is most likely not related to a neural signal, but possibly a
gut signal. Furthermore, the mouse model we used is leptin deficient making it unlikely
that the mechanism of reduced food consumption involved the leptin signaling pathway.
Instead, it is possible that inhibition of an orexigenic peptide, such as ghrelin, is involved.
Concentrations of didemnin B following i.p. administration in mice are greatest in the
liver, digestive tract, and pancreas (Beasley et al., 2005). The stomach is the major source
of circulating ghrelin, however ghrelin is also released by the intestine and pancreas
(Wierup et al., 2014). Therefore, it is possible that in our study didemnin B, by inhibiting
protein synthesis in the digestive tract and pancreas, inhibited ghrelin production
resulting in appetite suppression and decreased food consumption in ob/ob mice. Further
studies are required to test this possibility.
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4.3

Didemnin B Treatment Reduces Hepatic Lipid Contents and
Improves Plasma Lipid Profiles in Obese Mice
Treatment of obese mice with didemnin B decreased liver triglyceride content

while increasing plasma VLDL and triglycerides suggesting that intervention with
didemnin B was able to normalize hepatic steatosis and triglyceride-rich lipoprotein
export. The decrease in plasma triglyceride and VLDL levels, and increase in liver
triglyceride content we observed in ob/ob control mice were consistent with findings in
other studies. Ob/ob mice are well characterized, and are known to have increased ER
stress in the liver (Ai et al., 2012) that impairs the ability of the hepatocyte to produce
and secrete VLDL (Camus et al., 1988; Coenen et al., 2007; Li et al., 1997; Wiegman et
al., 2003). This results in decreased export of triglyceride in VLDL, decreased circulating
levels of VLDL, and increased hepatic triglyceride accumulation that contributes to
steatosis. The effects of didemnin B treatment on hepatic lipid contents and on plasma
triglyceride and VLDL concentrations can be explained by decreased food intake.
Decreased delivery of dietary lipids to the liver can decrease steatosis and associated
hepatocyte ER stress, allowing the liver to restore export of triglyceride in VLDL. This
concept is supported by our observations of increased plasma triglyceride and VLDL
triglycerides, to levels observed in lean control mice, in both didemnin B treated and
calorie restricted ob/ob mice. Unlike the changes observed in liver and plasma
triglycerides, increased liver cholesteryl ester content and decreased plasma cholesterol
and LDL were unique to mice treated with didemnin B. An increase in LDL receptor
(LDLR) expression and subsequent LDL clearance by the liver could explain the
increased hepatic cholesteryl ester content, decreased plasma cholesterol levels and levels
of cholesterol associated with LDL observed in these mice. Further experiments would be
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required to confirm that LDLR expression and LDL clearance were increased by
didemnin B treatment. However, from the data in this thesis, it can be concluded that
didemnin B treatment may play a role in normalizing hepatic triglyceride content and
plasma triglyceride levels, as well as normalizing plasma lipoprotein profiles in ob/ob
animals by mitigating eEF1A-1 mediated ER stress.

4.4

Didemnin B Treatment Improves Markers of Hepatic
Lipotoxicity and ER Stress in Obese Mice
Plasma liver enzymes and some protein markers of ER stress were normalized in

obese mice treated with didemnin B. The reduction in plasma ALT and AST levels
observed could be explained by decreased food intake, and subsequent reductions in
lipotoxic cell stress and hepatocyte injury (Tsutsumi et al., 2011). Moreover, these results
indicate that treatment with didemnin B at this low dose (50 µg/kg) does not cause
hepatic toxicity. Although there was no difference in eIF2α phosphorylation in the livers
of didemnin B treated ob/ob mice, hepatic GRP78 protein content and phosphorylation of
JNK were decreased in didemnin B treated animals. The decrease in GRP78 protein
content and JNK phosphorylation, accompanied by a lack of change in eIF2α
phosphorylation, suggests that didemnin B does not prevent the initiation of the UPR but
does reduce ER stress by inhibiting downstream UPR and ER stress markers (Ibrahim
and Gores, 2012; Zhou and Liu, 2014). Previous studies have implicated eEF1A-1 as a
mediator of hepatic ER stress in vitro through its contribution to protein synthesis in the
setting of excess ER anabolic burden (Stoianov, 2013; Stoianov et al., 2015). These
previous findings, along with evidence presented in this thesis suggest that inhibition of
eEF1A-1 with didemnin B mitigates hepatic ER stress and subsequent lipotoxicity during
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NAFLD. Thus, it is possible that eEF1A-1 may play a role in the progression of this
chronic liver disease.

4.5

Improved Glucose Homeostasis in Obese Mice Can Be
Explained by Decreased Food Intake
Our data also show that treatment with didemnin B improves glucose

homeostasis. However, the effects of didemnin B treatment on glucose tolerance and
insulin sensitivity could be completely explained by decreased food intake. Our findings
are consistent with previous studies in ob/ob and db/db mice that show caloric restriction
improves glucose tolerance and insulin sensitivity (Stranahan et al., 2009; Tsutsumi et al.,
2011; van den Hoek et al., 2008). However, i.p. administration of didemnin B is known
to result in accumulation of this molecule in the pancreas. Therefore, pancreatic tissue
should be further examined to ensure that decreased plasma insulin observed in didemnin
B treated mice is due entirely to improved insulin sensitivity, and not the result of
pancreatic islet damage and/or inhibition of protein synthesis in the pancreas.

4.6

Inhibition of eEF1A-1 Peptide Elongation Function and
Cultured Hepatocyte Responses to Palmitate-Induced ER
Stress and Cell Death
In HepG2 cells, didemnin B (at its IC50 for protein synthesis) decreased palmitate-

induced upregulation of GRP78, but not the initiation of the UPR as measured by eIF2α
phosphorylation. Inhibition of eEF1A-1 peptide elongation function with didemnin B
under basal conditions did not trigger feedback stimulation of eIF2α phosphorylation.
This is consistent with our in vivo data and with recent studies in yeast strains with
mutations that interfere specifically with the peptide elongation function of eEF1A-1
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(Perez and Kinzy, 2014). Didemnin B also prevented the recovery of protein synthesis
that is known to occur during chronic ER stress and contributes to subsequent cell death
by increasing the burden on the already overwhelmed ER (Guan et al., 2014). It is likely
that didemnin B does not prevent the early effects of excess palmitate on ER membrane
composition (Borradaile et al., 2006b) that result in ER stress and phosphorylation of
eIF2α. However, as supported by the observed decrease in palmitate-induced
upregulation of GRP78 and sustained suppression of protein synthesis with didemnin B
in the presence of palmitate, it is likely that inhibition of eEF1A-1 dependent protein
synthesis at the ER is protective during lipotoxicity. This concept is further supported by
studies that suggest alleviating ER stress and the accumulation of unfolded and misfolded
proteins may be a viable therapeutic strategy for the treatment of NAFLD (Ibrahim et al.,
2011). Interestingly, specific inhibition of eEF1A-1 dependent protein synthesis using
didemnin B decreased palmitate-induced cell death, while inhibition of protein synthesis
using cycloheximide had no effect on cell survival. This suggests that protection from
palmitate-induced cell death may be specific to eEF1A-1 dependent protein synthesis,
perhaps due to its predominant localization to the ER. Together, the findings of this thesis
support a role for eEF1A-1 dependent protein synthesis in the promotion of lipotoxicity,
and suggest that inhibition of this activity with didemnin B reduces ER stress and
lipotoxic cell death in hepatocytes.
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Figure 4.1 Working model of the role of eEF1A-1 and didemnin B in the pathways
involved in hepatocyte lipotoxicity.
Excess saturated fatty acids, such as palmitate, can overwhelm the ability of a hepatocyte
to store them as triglycerides (lipid droplets), to catabolise them through β-oxidation in
the mitochondria, and to export them as triglycerides in lipoproteins. This can result in
the production of reactive oxygen species (ROS) which can lead to oxidative and ER
stress. Excess palmitate can also impair the structure and integrity of the ER membrane.
Oxidative stress and impaired ER structure leads to a release of ER calcium which can
initiate cell death pathways. Under basal conditions, eEF1A-1 (green circles) is
predominantly localized to the ER. Fatty acid overload results in the mobilization of
eEF1A-1 from the ER to the actin (red circles) cytoskeleton. eEF1A-1 may mediate
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changes in the actin cytoskeleton that are necessary for the progression of cell death
and/or may promote cell death through its protein synthetic activity at the ER. Didemnin
B (DB) specifically binds GTP-bound eEF1A-1 (black circles) at the ribosome, and
inhibits peptidyl-tRNA translocation and peptide elongation. At the ER, this alleviates
ER stress by preventing any further protein synthetic burden, resulting in protection from
cell death, possibly including apoptosis, necrosis, and anoikis.
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4.7

Future Directions and Limitations of Study
A working model for the roles eEF1A-1 and didemnin B play in the

hepatocellular response to saturated fatty acid induced stress is summarized in Figure 4.1.
Based on this model, and our observations in obese mice treated with didemnin B, several
lines of further experimentation are warranted. However, perhaps the most critical
experiment required to support the hypothesis outlined in Section 1.6, is to determine
whether or not didemnin B inhibits total protein synthesis in the liver in vivo. This is a
challenging experiment to perform in obese mice undergoing chronic ER stress because
protein synthesis is already suppressed. However, it may be possible to measure plasma
albumin levels in lean control mice upon treatment with didemnin B to address this
question. It is important to note that any observed changes in this setting could also be
attributed to impaired kidney function (Seimiya et al., 2014).
We have hypothesized that the reduction in food consumption observed in ob/ob
animals treated with didemnin B may be due to the inhibition of ghrelin production or
action. To test this hypothesis, we could assess circulating plasma ghrelin levels and
ghrelin expression in tissues known to produce this hormone, such as the pancreas,
stomach and intestine (Yada et al., 2008).
To further confirm the effects of didemnin B on improving clinical characteristics
of NAFLD, histological sections of hepatic tissue stained with H&E could be graded
using the NAFLD Activity Score (NAS) scoring system described by Takahashi and
Fukusato (2014). Using this scoring system, the severity of NAFLD is evaluated based on
the presence of steatosis, Mallory-Denk bodies, lobular inflammation, and hepatocyte
ballooning, to accurately identify the disease from mild (benign steatosis) to severe
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(NASH). Mice on a C57BL/6J background, as is the case for ob/ob mice, do not develop
fibrosis with NAFLD (Anstee and Goldin, 2006), thus disease grading for this method
would be limited to pre-fibrotic NAFLD.
To further support our conclusion that treatment with didemnin B improves
hepatic lipotoxicity in obese mice with NAFLD, the expression of several genes could be
examined by real-time quantitative polymerase chain reaction (rtQPCR). Data about
metabolic gene expression would help to determine if the effects of didemnin B were
associated with changes in de novo lipogenesis, lipid export, or clearance from the
circulation and catabolism. Hepatic diglyceride acyltransferase (DGAT), fatty acid
synthase (FAS), and SREBP-1c expression would provide further insight into the effects
of didemnin B on liver triglyceride, fatty acid, and cholesterol synthesis, respectively
(Nakamura et al., 2014). LDLR expression, along with lipoprotein kinetic studies, would
help to elucidate whether the increased hepatic cholesteryl ester content, decreased
plasma cholesterol levels and levels of cholesterol associated with LDL we observed in
didemnin B treated animals were due to upregulation of LDLR and a subsequent increase
in LDL clearance. Furthermore, hepatic XBP1 expression would provide us with further
information about the mitigating effects of didemnin B treatment on ER stress (Henkel
and Green, 2013).
Didemnin B is known to distribute to the pancreas in rodent models (Beasley et
al., 2005). Due to the reduction in plasma insulin levels we observed in didemnin B
treated mice, it is important to confirm whether this is solely a result of improved glucose
homeostasis or due to impaired insulin production resulting from the inhibition of protein
synthesis in pancreatic β-cells. To determine if treatment with didemnin B alters islet size
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and insulin content relative to control and calorie restricted animals, pancreatic serial
sections will be stained for insulin, and islet areas and insulin-positive islet cells will be
quantified.
The chemotherapeutic activity of didemnin B was clinically tested in humans,
however, these phase II clinical trials failed due to ineffective antitumor activity
combined with intestinal toxicity (Benvenuto et al., 1992; Marco et al., 2004; Mittelman
et al., 1999; Shin et al., 1994; Shin et al., 1991). Doses of didemnin B in these trials
ranged from 3.47 mg/m2 to 9.1 mg/m2 (Shin et al., 1991), which is approximately 0.09
mg/kg to 0.25 mg/kg. Although a much lower dose (50 µg/kg) was used for the studies in
this thesis, and no overt evidence of illness or functional systemic toxicity was observed
in didemnin B treated animals, intestinal sections should be further assessed. Intestinal
toxicity could be determined by staining serial sections of ileum and jejunum with H&E
and examining sections for apparent pathology using light microscopy. In addition,
sections could be stained for markers of enterocyte proliferation such as Ki67, to
determine if didemnin B treatment results in abnormal cell proliferation (Bacchi and
Gown, 1993; Yu and Filipe, 1993; Yu et al., 1992)
As discussed earlier, the ob/ob mouse model is resistant to NAFLD associated
fibrosis (Anstee and Goldin, 2006). Therefore, to investigate the role of eEF1A-1 and the
effect of didemnin B treatment on NASH and fibrosis in vivo, a different mouse model
would be required. Studies using 129/SVJ mice fed a high fat diet for 6 months indicate
that these animals develop obesity, hepatic steatosis, insulin resistance, and liver fibrosis
(Syn et al., 2009). This diet-induced model of NAFLD and fibrosis would be more
representative of the disease found in the human population and would be useful to
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conduct further experiments to investigate the role of eEF1A-1 in the end stages of
NAFLD.
Finally, the liver is composed of a variety of cells other than hepatocytes,
including hepatic stellate cells, sinusoidal endothelial cells, and Kupffer cells (Peverill et
al., 2014). Activated hepatic stellate cells are myofibroblast-like cells that produce
extracellular matrix and are the principle cell type responsible for hepatic fibrosis
associated with NASH (Fujii and Kawada, 2012). Our knowledge of lipotoxicity in
hepatic stellate cells is limited, but it is possible that eEF1A-1 may play a role in the
progression of fibrosis, especially given its function in protein synthesis under conditions
of cell stress. Further experiments investigating the effects of reduced eEF1A-1
expression and activity in primary hepatic stellate cells and in a mouse model of NAFLD
fibrosis may provide insight into the role(s) that eEF1A-1 plays throughout the entire
liver during all stages of NAFLD progression.
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